Key facts
- Sime Diagnostics’s last known valuation is $31.7M (Feb 2026).
- It has raised $14.1M across 1 recorded rounds; the latest was Seed Round ($626K) in Sep 2019.
- Notable investors include Microsoft for Startups, Consilience Ventures, DigitalHealth.London Accelerator, Grow London, Horizon 2020 — 8 tracked in total.
- Sime Diagnostics has filed 3 Form Ds with the SEC since 2014, most recently May 2020 ($626K sold to 2 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Sime Diagnostics
Funding rounds
1 roundsAbout Sime Diagnostics
Developer of an artificial intelligence-powered medical diagnostics platform designed for acute and intensive care settings. The company's platform utilizes machine learning and proprietary hardware for rapid, reagent-free point-of-care testing by analyzing gastric aspirate samples to measure biomarkers reflecting lung maturity, enabling clinicians to assess risk for respiratory distress in newborns and facilitate timely, targeted respiratory care within the first hour of life.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2014
- Employees
- 32
- Website
- simedx.com/
- Ownership
- Privately Held (backing)
Sime Diagnostics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Sime Diagnostics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Sime Diagnostics in its N-PORT filings yet. We sweep new filings monthly.